HealthManagement, Volume 1 - Issue 1, November-December 2007

Medtronic has announced the European introduction of Reveal® XT, the first Insertable Cardiac Monitor that offers longterm and continuous monitoring of Atrial Fibrillation (AF). All other current monitoring tools are either for a limited period or on an intermittent basis. Longterm, continuous monitoring means that a clinician no longer needs to rely only on incomplete data to evaluate how AF may be progressing or treatment effectiveness. The device recently received the CE (Conformité Européenne) Mark, and the first implant of Reveal XT took place at Asklepios Klinik St. Georg in Hamburg, Germany by Prof. Karl- Heinz Kuck, M.D. The Reveal XT insertable cardiac monitor is not currently available for sale in the United States.

«« Boston Scientific Announces Approval of New Cardiac Devices


Siemens Japan Acquires Majority Stake of Mochida Siemens Medical Systems »»